Thu, Jul 31, 2014, 7:10 PM EDT - U.S. Markets closed


% | $
Click the to save as a favorite.

Insmed Incorporated Message Board

  • insm_truth_teller insm_truth_teller May 19, 2013 8:30 AM Flag


    Once granted, the composition of matter patent provides exclusivity in any of the European Patent Office's member states where Insmed chooses to file at least through July 19, 2026.

    The U.S. Patent and Trademark Office issued a composition of matter patent covering the Company's liposomal amikacin for inhalation in August 2012, with U.S. exclusivity extending until at least August 2028.
    & Nebulizer device exclusivity for minimum of 15 years

17.09-0.42(-2.40%)Jul 31 3:59 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.